CytomX Therapeutics
CytomX Therapeutics is an oncology-focused biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative antibody therapeutics utilizing its proprietary Probody technology platform. This platform enables the creation of proteolytically-activated antibodies designed to improve targeting of tumor cells while minimizing effects on healthy tissues. The company is advancing several clinical-stage product candidates, including CX-072, a therapeutic targeting programmed cell death ligand 1; CX-2009, a drug conjugate against CD166; and BMS-986249, a CTLA-4 Probody therapeutic for metastatic melanoma, among others. CytomX Therapeutics collaborates strategically with major pharmaceutical companies such as AbbVie, Amgen, and Bristol-Myers Squibb to further its mission of providing more effective and less toxic therapies for cancer and inflammatory diseases. Founded in 2008, the company aims to enhance therapeutic options for patients facing severe illnesses.
Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.